alexa Serine Protease Homolog From Snake Venom, A Promising New Anticoagulant Lead Molecule
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

7th World Hematologists Congress
May 08-09, 2017 Barcelona, Spain

Igor Krizaj, Latinovic Z, Leonardi A, Pungercar J, Koh C Y and Kini R M
Jožef Stefan Institute, Slovenia
Jožef Stefan International Postgraduate School, Slovenia
National University of Singapore, Singapore
ScientificTracks Abstracts: J Blood Disord Transfus
DOI: 10.4172/2155-9864-C1-022
Abstract
Most frequently used anticoagulant therapies may induce severe complications. To overcome these limitations, new anticoagulants have been intensively searched for. We report here the purification and characterization of a glycoprotein from the venom of the nose-horned viper (Vipera ammodytes), which significantly prolonged activated partial thromboplastin time in human plasma. Amino acid sequence of this protein (VaaSPH) revealed it as a serine protease possessing two mutations in its catalytic triad that renders it enzymatically inactive. Detailed analysis of the mechanism of blood coagulation inhibition by VaaSPH unveiled that the molecule inhibits the activity of tenase and prothrombinase complexes, with IC50 values of 142 nM and 134 nM, respectively. It was demonstrated that inhibition of the complexes formation was due to the binding of VaaSPH to blood coagulation factors VII, IX and X, to their activated forms and to FVa and FII. In addition, VaaSPH was also found to bind specifically to phosphatidylserine, a negatively charged phospholipid, which directed the assembly of the enzyme–cofactor complexes on membrane surface of platelets. Three-dimensional structure comparison of FVII, FIX, FX, FII and their respective activated forms suggested two areas on their surfaces, in proximity of their active sites, where VaaSPH binds. Such a proposal was also experimentally supported. As a potent nonenzymatic and coagulation factor active-site independent inhibitor of blood coagulation process, VaaSPH is unique and therefore, very interesting for a further characterization to design, based on its structure, a novel family of selective coagulation factor inhibitors of therapeutic relevance for anticoagulant therapy.
Biography

Igor Križaj completed his Doctoral studies at Jožef Stefan Institute in Ljubljana (JSIL) and at Imperial College in London. He completed his Post-doctorate studies at Institute Pasteur in Paris. He is the Head of Department of Molecular and Biomedical Sciences at JSIL and full Professor of Biochemistry at University of Ljubljana. He has published more than 130 research papers in the SCI-journals. He has been serving as an Editorial Board Member at several scientific journals and as Secretary of the European Section of the International Society on Toxinology.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords